Lexeo Therapeutics Inc. C...

4.09
-0.02 (-0.49%)
At close: Mar 28, 2025, 3:59 PM
3.93
-3.91%
After-hours: Mar 28, 2025, 04:49 PM EDT

Company Description

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.

The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.

It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.

The company was incorporated in 2017 and is based in New York, New York.

Lexeo Therapeutics Inc. Common Stock
Lexeo Therapeutics Inc. Common Stock logo
Country United States
IPO Date Nov 3, 2023
Industry Biotechnology
Sector Healthcare
Employees 72
CEO R. Nolan Townsend

Contact Details

Address:
345 Park Avenue South
New York,
United States
Website https://www.lexeotx.com

Stock Details

Ticker Symbol LXEO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001907108
CUSIP Number 52886X107
ISIN Number US52886X1072
Employer ID 85-4012572
SIC Code 2836

Key Executives

Name Position
R. Nolan Townsend Chief Executive Officer & Director
Dr. Kyle Rasbach Ph.D., Pharm.D. Chief Financial Officer
Dr. Eric Adler M.D. Chief Medical Officer & Head of Research
Dr. Jose Manuel Otero Ph.D. Chief Technical Officer
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
Dr. Sandi See Tai M.D. Chief Development Officer
Jenny R. Robertson J.D. Chief Business & Legal Officer
Ryan McHenry Vice President & Corporate Controller

Latest SEC Filings

Date Type Title
Mar 24, 2025 S-8 POS Filing
Mar 24, 2025 424B5 Filing
Mar 24, 2025 S-8 Filing
Mar 24, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 21, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing